Log In
BCIQ
Print this Print this
 

Glanglion progenitor cell therapy

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionRetinal ganglion cells (RGCs)
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPreclinical
Standard IndicationGlaucoma
Indication DetailsTreat glaucoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$379.0M

$379.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/10/2016

$379.0M

$379.0M

0

Get a free BioCentury trial today